Rosuvastatin

Generic Name: Rosuvastatin

Brand Names: Crestor, Ezallor, Roszet

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈FN_₃O_₆S

CAS Number: 287714-41-4

Unique Ingredient Identifier: 413KH5ZJ73

Background: Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...

Indication: The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...

Associated Conditions: Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia

Associated Therapies: Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases

Clinical Trials

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Phase 1

Not yet recruiting

Conditions: Dyslipidemia

Interventions: Drug: Ezetimibe
Drug: AZD0780
Drug: Rosuvastatin
Drug: Bempedoic Acid
Drug: Placebo

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 120

Registration Number: NCT06742853

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Not yet recruiting

Conditions: Primary Hypercholesterolemiia
Mixed Dyslipidemia

Interventions: Drug: Bempedoic acid
Drug: Ezetimibe
Drug: Rosuvastatin
Drug: Atorvastatin

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-14

Lead Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Target Recruit Count: 2000

Registration Number: NCT06686615

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: Digoxin
Drug: Rosuvastatin
Drug: Divarasib

First Posted Date: 2024-11-07

Last Posted Date: 2024-12-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 19

Registration Number: NCT06677957

Locations: 🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Adult Subject
Overweight Subject

Interventions: Drug: Repaglinide
Drug: Atorvastatin
Drug: Digoxin
Drug: Rosuvastatin
Drug: HDM1002

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT06601517

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

A Study of LY4065967 in Healthy Japanese Participants

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: LY4065967
Drug: Placebo
Drug: Rosuvastatin

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 69

Registration Number: NCT06594159

Locations: 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: Danuglipron
Drug: Atorvastatin
Drug: Rosuvastatin

First Posted Date: 2024-08-22

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT06567327

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps - Mra, Llc., South Miami, Florida, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States